TriangleNCT00848926 · OUTCOME
B Symptom Resolution
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 12 months
What was measured
Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.
Analysis population: Participants with B symptoms at baseline
Groups in this outcome
Brentuximab Vedotin
Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
| Group | Source count |
|---|---|
| Brentuximab Vedotin | 35 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Brentuximab Vedotin | 77 | Not reported | 59.9 | 89.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 59.9
- upper Limit
- 89.6
- value
- 77
- denoms
- counts
- group Id
- OG000
- value
- 35
- units
- Participants
- description
- Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
- id
- OG000
- title
- Brentuximab Vedotin
- param Type
- NUMBER
- population Description
- Participants with B symptoms at baseline
- reporting Status
- POSTED
- time Frame
- up to 12 months
- title
- B Symptom Resolution
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- percent of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice